Lisata Therapeutics (NASDAQ:LSTA) Rating Reiterated by HC Wainwright

Lisata Therapeutics (NASDAQ:LSTA)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research report issued on Thursday, Benzinga reports. They presently have a $15.00 price target on the stock. HC Wainwright’s price target points to a potential upside of 466.51% from the stock’s previous close.

Lisata Therapeutics Stock Performance

LSTA stock opened at $2.65 on Thursday. Lisata Therapeutics has a 1-year low of $1.95 and a 1-year high of $4.53. The business has a fifty day moving average price of $3.02 and a 200-day moving average price of $2.71.

Lisata Therapeutics (NASDAQ:LSTA) last posted its quarterly earnings results on Thursday, February 29th. The company reported ($0.66) earnings per share for the quarter, topping the consensus estimate of ($0.86) by $0.20. On average, equities analysts predict that Lisata Therapeutics will post -3.08 EPS for the current fiscal year.

Institutional Trading of Lisata Therapeutics

A hedge fund recently raised its stake in Lisata Therapeutics stock. BML Capital Management LLC raised its stake in shares of Lisata Therapeutics, Inc. (NASDAQ:LSTA) by 10.7% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 269,839 shares of the company’s stock after purchasing an additional 26,000 shares during the period. Lisata Therapeutics accounts for about 0.6% of BML Capital Management LLC’s investment portfolio, making the stock its 24th biggest holding. BML Capital Management LLC owned approximately 3.31% of Lisata Therapeutics worth $737,000 as of its most recent filing with the SEC. 8.94% of the stock is owned by hedge funds and other institutional investors.

About Lisata Therapeutics

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.